English abstract
Objectives: The main objective of this study is to ensure all
patients undergone kidney transplantation receives appropriate
standard PCP prophylaxis soon after transplantation, unless
contraindicated.
Methods: A prospective study included all kidney transplantation
recipients from January 2008 to August 2008. A data collection
sheet was designed and reviewed in focus group meetings and
modified accordingly. The subjects were followed-up during
the admission for transplantation to the date of discharge. The
discharge prescriptions were screened to ensure all the kidney
transplantation recipients were prescribed appropriate PCP
prophylaxis before discharge. All prescriptions with NO PCP
prophylaxis were intervened by the clinical pharmacist. The
focus group meetings suggested designing a questionnaire using
likerts scale. The purpose was to highlight doctors' perception
towards PCP prophylaxis for renal transplant recipients. The
questionnaires were distributed to all the nephrology doctors
(consultants, senior specialists and medical officers). The data
were entered in the data collection sheet and were analyzed by
using simple statistical methods.
Results: Almost 80% of the prescriptions did not included
(TMP/SMX) for PCP among which 20% of the prescriptions
were for patients with G6PD deficiency. The clinical pharmacist's
interventions resulted that all discharge prescriptions were
modified and (TMP/SMX) was prescribed for patients who
were legible for a PCP prophylaxis
Conclusion: In the absence of prophylaxis, the incidence of
PCP in solid organ transplant recipients ranges from 6.8%
to 22%, necessitating PCP prophylaxis for at least 6 months
following transplantation. Despite the widespread knowledge on
PCP prophylaxis, most of the patients were discharged with no
prophylactic treatment for PCP. After pharmacist's intervention
the prescriptions were edited and PCP prophylaxis was added.
